Chronic Hepatitis b With Multidrug Resistance Clinical Trial
Official title:
Tenofovir-based Combination Therapy or Monotherapy for Multi-drug Resistant Chronic Hepatitis B; Real World Data From Multicenter Cohort Study
Treatment of multidrug resistant (MDR) chronic hepatitis B (CHB) is still a challenging issue. Hence, the investigators will perform a multicenter prospective cohort study for the evaluation of tenofovir disoproxil fumarate (TDF)-based therapy for MDR CHB at real life settings.
Inclusion criteria were CHB patients with resistance to more than two classes of
nucleos(t)ide analogues (NA) and hepatitis B virus (HBV) DNA level ≥200 IU/mL.
Patients will receive either TDF-base combination therapy or TDF monotherapy. The primary end
point is virologic response (VR) defined by an undetectable HBV DNA (<20 IU/mL) at month 36.
;